CD14 and COVID-19: Among the monocytes affected by COVID-19, CD14+CD16- C. Mono and CD14+CD16+ Int. Mono accounted for 91-96% of total monocytes, which remained high in convalescent severe patients (68%) relative to healthy donors (39%) (Supplementary Figure 4D), which is in agreement with Zhou et al.